## 510(K) SUMMARY (as required by 807.92 9c)

Submitter of 510(K):

KLS-Martin, L.P.

11239-1 St. Johns Industrial Pkwy. S.

Jacksonville, Florida 32246

Phone:

904-641-7746

Fax:

904-641-7378

Contact Person:

Jennifer Damato

**Date of Summary:** 

Trade Name:

Molina Orbital Malar Distractor

Classification Name:

**Predicate Device:** 

K945500 – Wells Johnson Fixation System

**Device Description/** 

Comparison:

The KLS-Martin Molina Orbital Malar Distractor is an internal distractor for bone elongation, which takes into account the special conditions of the facial skeleton. The device is used for the correction of craniosynostosis and congenital midface deficiencies. An osteotomy is made in the selected skeletal area in which the distraction device is to be placed. The device is anchored to the bone by 1.5mm KLS-Martin Titanium bone screws (K944565) and the one of the various attachment pivots (see brochure). The selection of the appropriate attachment pivot depends on the individual deformity, as well as the condition of the placement point. Distraction is accomplished by the use of a threaded rod, which is activated at a rate of 1mm per day, achieving callus distraction.

Intended Use:

The KLS-Martin Molina Orbital Malar Distractor is intended for use in the treatment of cranial and midface conditions such as syndromic craniosynostosis and congenital midface deficiencies in which osteotomies and gradual bone distraction are indicated. This device is intended to provide temporary stabilization and gradual lengthening of the cranial and midface bones.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

## JAN 2 3 2001

Mr. Art Ward Regulatory Specialist KLS-Martin L.P. 11239-1 St. John's Industrial PKWY. South Jacksonville, Florida 32246

Re: K003883

Trade Name: Molina Orbital Malar Distractor

Regulatory Class: II Product Code: JEY

Dated: December 8, 2000 Received: December 15, 2000

Dear Mr. Ward:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. Α substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic

Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4692. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely Yours,

Timothy A. Ulatowski

Director

Division of Dental, Infection Control and General Hospital Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

510(k) Number (if known): <u><b>km 5843</b></u>			
Device Name: Molina Orbital Malar Distractor			
Indications For Use:			
The KLS-Martin Molina Orbital Malar Distractor is intended for use in the treatment of cranial and midface conditions such as syndromic craniosynostosis and congenital midface deficiencies in which osteotomies and gradual bone distraction are indicated. This device is intended to provide temporary stabilization and gradual lengthening of the cranial and midface bones.			
(PLEASE DO NOT WRITE BELOW THIS	LINE - CON	ITINUE ON ANOTHER P	AGE <del>IS NEEDED</del> )
Concurrence of CDRH, Office of Device Evaluation (ODE)			
	e e		
Prescription Use(Per 21 CFR 801-109)	OR	Over-The-Counte	r Use
(. 5. 21 51 ( 55 ( 55)			(Optional Format 1-2-96)